NEW YORK – The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as a treatment for patients with ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

The data displayed for this chart goes back to 1997, however we hope to be able to offer deeper historic information at a future point ...

The data displayed for this chart goes back to 1994, however we hope to be able to offer deeper historic information at a future point ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.